Holen Sie sich die Stockscreener-App
29.94
1.87%
-0.57
Schlusskurs vom Vortag:
$30.51
Offen:
$30.85
24-Stunden-Volumen:
6.34M
Relative Volume:
1.68
Marktkapitalisierung:
$3.73B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-472.34M
KGV:
-7.2216
EPS:
-4.1459
Netto-Cashflow:
$-340.33M
1W Leistung:
-15.80%
1M Leistung:
-10.63%
6M Leistung:
-13.97%
1J Leistung:
+7.39%
1-Tages-Spanne:
$29.90
$31.09
1-Wochen-Bereich:
$29.90
$35.19
52-Wochen-Spanne:
$25.77
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
29.94 | 4.43B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
3 Emerging Biotech Stocks With Significant Upside Potential - Yahoo Finance
Free cash flow of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - theglobeandmail.com
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
3 Non-AI Growth Stocks That Have Massive Upside - Yahoo Finance
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks - TradingView
Viking Therapeutics (VKTX) Raises $575M in Upsized Stock and Con - GuruFocus
Viking Completes $575 Million Financing Round - Intellectia AI
Form 8K Viking Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Viking Therapeutics Raises $547.8 Million via Equity Sale and 2.00% Convertible Notes - TradingView
Viking Therapeutics nets ~$550M in proceeds from latest offering - TradingView
Viking Therapeutics raises $575 million in dual offering - Investing.com
Viking Therapeutics raises $575 million in dual offering By Investing.com - Investing.com Australia
Viking Therapeutics (VKTX) Closes Upsized Stock and 2.00% Convertible Notes Offerings, ~$575M Gross - TradingView
Viking Therapeutics, Inc. Bonds — Corporate Bond Rates - TradingView
Viking Therapeutics (VKTX): VK2735 Data Look Strong, but Cash Burn Still Matters - AlphaStreet
Viking Therapeutics posts strong obesity drug t... - Pluang
Viking Therapeutics Draws Investor Investigations - stl.news
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX) - Seeking Alpha
Investigation launched into Viking Therapeutics' officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Morningstar
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? - The Motley Fool
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution - Yahoo Finance
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks - Stocktwits
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing - Yahoo Finance
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users? - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits
Viking Therapeutics Stock (VKTX) Opinions on Positive Obesity Drug Data Release - Quiver Quantitative
What Viking Therapeutics Stock Means For Shareholders After Obesity Drug Data And $500 Million Raise - simplywall.st
VKTX 10-Q FilingsViking Therapeutics, Inc SEC 10-Q - Stock Titan
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (NASDAQ:VKTX) - Seeking Alpha
Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data? - Yahoo Finance
Biotech Stocks To ResearchSeptember 25th - MarketBeat
VKTX Form 4 FilingsViking Therapeutics, Inc SEC Form 4 - Stock Titan
Is Viking Therapeutics, Inc. (VKTX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Form 424B5 Viking Therapeutics Inc For: 25 September - Investing.com India
Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes - Legal Desire
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
Form 424B5 Viking Therapeutics Inc For: 25 September By Investing.com - Investing.com Canada
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
Viking Therapeutics (VKTX) Stock Looks Fully Priced Despite Its Huge Five Year Run - simplywall.st
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Viking Therapeutics Plunges After Upsized $500 Million Financing Prices at 16% Discount - finance.biggo.com
Viking Therapeutics Share Drop After Upsized Stock, Notes Offerings - moomoo.com
One investor reportedly took a third of Viking’s share sale - Yahoo Finance Australia
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):